Semax (Met-Glu-His-Phe-Pro-Gly-Pro) is a synthetic ACTH(4-7) analog with a C-terminal Pro-Gly-Pro tail that blocks peptidase degradation. It has been on the Russian List of Vital and Essential Drugs and used in acute neurology wards for ischemic stroke since the 1990s. Most Western nootropic discussion either treats it as a magic BDNF booster or dismisses the stroke data outright. Neither is quite right. Here is what the actual primary literature says.

The anchor trial: Gusev et al., 1997

The Russian registration evidence rests heavily on Gusev, Skvortsova et al., Zh Nevrol Psikhiatr Im S S Korsakova, 1997;97(6):26-34, conducted at the Institute of Stroke, Russian State Medical University.

Methodology.
Efficiency of Semax was studied in 30 patients in the acute period of hemispherical ischemic stroke, with a control group of 80 patients with strokes analogous in severity and location of damage, treated with conventional therapy. Different clinical rating scales were used for objectivization of severity and estimation of neurological defect.

The control of Semax influence on the functional state of the brain included monitoring of EEG with mapping, repeated analysis of somatosensory evoked potentials and their mapping.
Add-on design (Semax + standard care vs standard care), not placebo-controlled, not blinded in the modern sense. The trial was indexed in CENTRAL by Cochrane in 2001, which is worth noting because it means independent reviewers considered it a controlled trial of sufficient quality to enter the registry, not just a case series.

Results.
Including Semax in combined intensive therapy of acute ischemic stroke had some influence on the rate of restoration of damaged neurological functions in terms of increasing the regress of general cerebral and focal, especially motor disorders.
The EEG mapping and somatosensory evoked potential data was the more interesting piece, because it gave an objective physiological correlate to the clinical rating scale changes, which is harder to fake than a Barthel score.

The 2018 follow-up: BDNF as mechanistic bridge

Gusev, Martynov, Kostenko et al., 2018 tested Semax in the rehabilitation phase rather than the hyperacute window.

One hundred and ten patients after ischemic stroke (43 men, 67 women, mean age 58.0±9.7) were divided into early (89±9 days) and late (214±22 days) rehabilitation groups. Each group was subdivided into semax+ and semax- subgroups. Standard regimen of semax included 2 courses (6000 mcg/day) for 10 days with 20 day interval.
Primary endpoints: plasma BDNF, MRC motor scale, Barthel index.

Administration of semax, regardless of the timing of rehabilitation, increased BDNF plasma levels which remained high during the whole study period. In semax- subgroups high BDNF plasma levels were positively correlated with early rehabilitation.

Administration of semax and high BDNF levels accelerated improvement and ameliorated the final outcome of Barthel score index. There was a positive correlation between BDNF plasma levels and Barthel score, as well as between early rehabilitation and motor performance improvement. The correlation between BDNF plasma levels and Barthel score was modified by the timing of rehabilitation. Early rehabilitation and administration of semax increase BDNF plasma level, speed functional recovery, and improve motor performance.

Translation: the peptide raised peripheral BDNF, and the BDNF rise tracked with functional recovery. This is a mechanistic bridge, not just a clinical claim.

Methodological caveats (the honest part)

1. No modern placebo-controlled double-blind RCT exists in the English-language literature. As of late 2023, no published human Semax trials have been conducted outside Russia and post-Soviet states. The registration trials are Russian-language, add-on design, with unequal group sizes (30 vs 80 in the 1997 trial).
2. Outcome measures vary across studies. Some use Barthel and MRC, others use Scandinavian Stroke Scale or local Russian scales. Cross-study comparability is weak.
3. No NIHSS primary endpoint in the original registration trial. Some secondary sources cite NIHSS/mRS for Semax, but the foundational 1997 paper used a mixed clinical and electrophysiological panel.
4. Replication has been mechanistic, not clinical. The transcriptomic work, including Medvedeva et al., BMC Genomics 2014 showing immune and vascular gene modulation after pMCAO, and Dmitrieva et al., Cell Mol Neurobiol 2010 showing induction of Bdnf, Ngf, TrkB, TrkC, and TrkA transcription in the ischemic cortex, is solid and reproducible. The clinical replication is thinner.
5. Regulatory status is changing. Semax is scheduled for FDA Pharmacy Compounding Advisory Committee review on July 24, 2026 for the Section 503A Bulks List, with cerebral ischemia as one of the indications under evaluation. How PCAC handles non-English clinical data will be the deciding factor.

So what does this change for protocol thinking

For the nootropic-curious reader who is not a stroke patient: the stroke data is not directly portable to healthy-cognition use cases. What does port is the mechanism. The 2018 trial demonstrated that intranasal Semax at 6 mg/day raised plasma BDNF and that the rise was functionally meaningful in a damaged-brain context. That is a much stronger BDNF-elevation signal in humans than most nootropics can claim. The dose range used in stroke care (clinically 6,000-12,000 mcg/day for moderate stroke per Russian protocols) is roughly 10-20x what recreational nootropic users typically take, which should temper extrapolation in both directions.

At Klarovel, the editorial position has been that Semax's stroke literature is the most defensible part of its evidence base, but the 1990s trial design ceiling means it should be read as suggestive-with-mechanism rather than confirmatory.

What's the question this leaves you with: if a 1997 add-on trial plus a 2018 BDNF-correlation study is enough for Russian registration but not enough for FDA, where do you personally set the bar between "interesting peptide with mechanistic plausibility" and "actually use it"?